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ABSTRACT
DRUG RELEASING HYDROGELS FOR OPIOID USE DISORDER
by

Kaytlyn M. Crowe
Ease of access to prescription opioids and the strength of synthetic opioids have
contributed to the rise in over use disorders, overdose, and death rates during the opioid
epidemic. The current overdose standard of care, rescue NLX (NLX), is a competitive
antagonist to the µ-opioid receptor but has a relatively short period of action compared to
opioid agonists, especially synthetic agonists. Rises in the abuse of these synthetic and
semi-synthetic agents in recent years have shown the weaknesses of rescue NLX, as it
can leave overdose patients vulnerable to renarcotization and precipitated withdrawal. To
prevent both from occurring, we developed a slow release, subcutaneous NLX-loaded
peptide formulation for the potential management of renarcotization and precipitated
withdrawal. We synthesized a series of multidomain peptides with and without loaded
NLX and characterized their chemical, mechanical, and biophysical properties. The
nanofibrous ultrastructure was assessed with atomic force microscopy (AFM), the
secondary structure was probed by Fourier transform infrared spectroscopy in attenuated
total reflectance mode (FTIR-ATF), β-sheet formation was confirmed with circular
dichroism (CD), and the viscoelastic and thixotropic properties were measured via
oscillatory rheometry. In vitro cytocompatibility of the peptides was investigated using
3T3 fibroblast cells and a CCK8 assay. To evaluate the long-term release viability of the
peptides, an in vitro release study was performed for 7 and 30 days.

DRUG RELEASING HYDROGELS FOR OPIOID USE DISORDER

by
Kaytlyn M. Crowe

A Thesis
Submitted to the Faculty of
New Jersey Institute of Technology
in Partial Fulfillment of the Requirements for the Degree of
Master of Science in Biomedical Engineering
Department of Biomedical Engineering

August 2021

APPROVAL PAGE
DRUG RELEASING HYDROGELS FOR OPIOID USE DISORDER
Kaytlyn M. Crowe

Dr. Vivek A. Kumar, Thesis Advisor
Associate Professor of Biomedical Engineering, NJIT

Date

Dr. Rajesh Davé, Committee Member
Distinguished Professor of Chemical and Materials Engineering, NJIT

Date

Dr. James Haorah, Committee Member
Associate Professor of Biomedical Engineering, NJIT

Date

BIOGRAPHICAL SKETCH
Author:

Kaytlyn M. Crowe

Degree:

Master of Science

Date:

August 2021

Undergraduate and Graduate Education:
•

Master of Science in Biomedical Engineering,
New Jersey Institute of Technology, Newark, NJ, 2021

•

Bachelor of Science in Biomedical Engineering,
New Jersey Institute of Technology, Newark, NJ, 2020

Major:

Biomedical Engineering

Presentations and Publications:
Crowe, KM, Siddiqui, Z. “Evaluation of Injectable NLX-Releasing Hydrogels.” ACS
Applied Bio Materials. 2020 3 (11), 7858-7864. DOI: 10.1021/acsabm.0c01016
Panchal, D; Kataria, J; Patel, K; Crowe, KM; et al. “Peptide-Based Inhibitors for SARSCoV-2 and SARS-CoV.” Adv Therapeutics. Accepted.
Adil A, Fiore R, Gannamani S, Griffith A, Hang K, Crowe KM, Kumar VA. “Toothbrush
with Onboard Suction and Waste Storage for Evacuation of Aspirates.” Northeast
Bioengineering Conference: Undergraduate Research Showcase. 2021. Abstract and
Presentation.

iv

Mom and Dad, I couldn’t have done this without you

v

ACKNOWLEDGMENT
I would like to thank Dr. Vivek Kumar for his mentorship and guidance these past few years, as
well as for serving as my thesis advisor. I would also like to thank Dr. Rajesh Davè and Dr. James
Haorah for serving on my thesis committee and for their invaluable comments and suggestions. I
would like to acknowledge funding support from NSF 2041092, NIH R15 EY029504, NSF
IIP1903617, and NJIT startup funds. I would also like to thank past and present graduate students
in the KumarLab: Zain Siddiqui, KaKyung Kim, Abhishek Roy, Joe Dodd-o and Victoria
Harbour for their help, friendship, and mentorship. I would like to thank Dr. Amanda AcevadoJake for mentorship, leadership, and being a great role model for me. I would also like to thank
the many undergraduates for their hard work and dedication.

vi

TABLE OF CONTENTS
Chapter

Page

1 INTRODUCTION ……………………………...……..………………...……………….

1

1.1 Objective ..............................………………..……………………………….............

1

2 CHARACTERIZATION OF NLX LOADED PEPTIDES …..…………...........

4

2.1 Solid Phase Peptide Synthesis ..……………………………………………...……...

4

2.1.1 Synthesis Procedure …………………………....……………………….……

4

2.1.2 Hydrogel Formulation and Drug Loading …......………………………….…

5

2.2 Chemical and Ultrastructural Characterization ………….......………………….…..

6

2.2.1 Fourier Transform Infrared Spectroscopy ..……………...……………..……

8

2.2.2 Circular Dichroism …..………………………………………...………..…...

8

2.2.3 Atomic Force Microscopy ….………………………………..……................

10

2.3 Mechanical Characterization ….……………………………..…...............................

12

3 IN VITRO CYTOCOMPATIBILITY AND RELEASE ..………………..…....................

15

3.1 In Vitro Cytocompatibility ....…………………………………………..…...............

15

3.2 In Vitro Release Profile ….………………………………………………...…..........

18

4 CONCLUSION AND FUTURE STEPS ………………………………………………...

22

4.1 Conclusion ………………………...……………………………………….………..

22

4.2 Next Steps ….....……………………………………………………………..............

22

APPENDIX ………………………………………………………………………………….

24

REFERENCES ………………………………………………………………………...........

25

vii

LIST OF TABLES
Table
2.1

Page
Sequences and Properties of ASPs ……....………………..………………………….

viii

6

LIST OF FIGURES
Figure

Page

1.1

Design of amphiphilic self-assembling peptides (ASP) for release of NLX. ………

3

2.1

Fourier transform infrared (FTIR) fingerprint spectra. ……..………………………

7

2.2

Circular dichroism (CD) of peptide hydrogels. ……..………………………………

9

2.3

Atomic force microscopy (AFM) of diluted peptide hydrogels. ...………………….

11

2.4

Oscillatory shear thinning of peptide hydrogels. ...…………………………………

13

2.5

Thixotropic shear recovery of peptide hydrogels. ………..………………………...

14

3.1

Cytocompatibility assay of peptide hydrogels. ………………………………..……

17

3.2

Seven day release of NLX from peptide hydrogels. ………………………………..

20

3.3

Thirty day release of NLX from peptide hydrogels. ………………………………..

21

A.1 Mass spectroscopy of K2 and E2. ...………………………………………………….

24

ix

LIST OF SYMBOLS
β

Beta

µ

Mu

NLX

NLX

NTX

Naltrexone

K2

Positively charged, Lysine functionalized self
assembling peptide

E2

Positively charged, Glutamic Acid
functionalized self assembling peptide

w%

Weight percent

~

Approximately

x

LIST OF DEFINTIONS
NLX

Opioid antagonist- used to reverse opioid overdose

Naltrexone

Opioid antagonist- used in opioid abuse rehabilitation

xi

CHAPTER 1
INTRODUCTION

1.1

Objective

The µ-opioid receptor antagonist NLX (NLX) is the current gold-standard for opioid
overdose rescue1-4. However, NLX has a short half-life around 75 minutes5, and rescue
does must be administered several times to prevent a patient from going back into a state
of overdose, a phenomenon known as renarcotization6, 7. Overdoses caused by synthetic
opioids present a more significant risk of renarcotization1, and patients who are taken to a
hospital are put on intravenous NLX for 6 to 8 hours to prevent renarcotization5.
Unfortunately, there is a significant portion of opioid users8, 9 who do not enter hospital
care after receiving the first dose of NLX, leaving them wide open for renarcotization and
death from an overdose that could have been stopped2, 10, 11. This presents a gap in which
long-acting NLX formulations are needed to provide acute rescue benefit, reduce the
potential of renarcotization and, if tuned appropriately, potentially mitigate precipitated
withdrawal. The central hypothesis is that release of NLX can be controlled from
implantable subcutaneous self-assembling amphiphilic peptide hydrogel12-16 reservoirs
that promote prolonged NLX stability (Figure 1.1 A, B). These amphiphilic selfassembling peptides (ASPs) can sequester partially lipophilic/ hydrophobic drugs12, 15, 1719

such as NLX and can be formulated into thixotropic hydrogels in aqueous buffers at

physiological pH and ionic strength13-17,

20

. The objectives were the following: (a) to

synthesize a series of ASPs and characterize their biomechanical properties, (b)
determine the in vitro cytocompatibility, and (c) determine an in vitro release profile.

1

Ultimately, the goal is to be able to provide an injectable depot that can be administered
in clinics or after rescue NLX is used, in situations when patients are at most risk for
renarcotization (Figure 1.1 B, C, D). A longer term goal is also to provide a bridge
between the event of an overdose occurring and when a patient can begin rehabilitation
treatment.

2

Figure 1.1 Design of amphiphilic self-assembling peptides (ASP) for release of NLX.
(A) Noncovalent interactions initiate the self-assembly mechanism. Alternating
hydrophilic serine and hydrophobic leucine residues form hydrogen bonds, and assemble
into dimers, tetramers, nanofibers, and further form antiparallel β-sheet fibers. Drugs or
other small molecules can be added to the ASPs because of the aqueous (sucrose or
phosphate buffer) composition of the gel (B). (C) NLX can be dosed intramuscularly
(IM), intranasally (NAS), subcutaneously (SC), or intravenously (IV), but has a relatively
short half-life, especially when compared to other opioid type drugs. (D) NLX is a high
affinity µ-opioid antagonist, and preferentially binds to the receptor over agonists such as
heroin. (E) For prevention of renarcotization and more chronic opioid management, a 2week continuous release of NLX is considered.
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CHAPTER 2
CHARACTERIZATION OF NLX LOADED PEPTIDES

2.1

Solid Phase Peptide Synthesis

A peptide is a short chain of individual amino acid residues linked by peptides bonds,
where the carboxyl group (-CO2H) of one amino acid is bound to the amino group (-NH2)
of the next residue. The twenty common amino acids have side chain functional groups (R) that can have a negative, positive, or neutral electric charge, polarity, or other
attributes that will carry over into the peptide that is created21. The overall charge of
peptides, as well as local charge distribution, can drastically alter the solubility of
peptides, as well as their biological activity21. While NLX has no net formal charge at pH
7, K2 is positively charged and E2 is negatively charged. Two oppositely charged ASPs
were chosen to see if the charge of the scaffold had a difference on the release of NLX
from the ASP scaffolds.
2.1.1 Synthesis Procedure
Solid phase peptide synthesis (SPPS) is the method of choice for most peptide synthesis
today22. SPPS has advantages over both liquid phase peptide synthesis and recombinant
peptide synthesis in that it allows the user increased control over the physical and
electrochemical properties of the peptide in question, the process is now automated with a
relatively short production cycle, and allows for the rapid synthesis of medium chain
peptides22, 23 (<50 amino acids). However, as with all peptide synthesis methods, the raw
materials are expensive, and the purification process for SPPS products can be complex
and lengthy. Fmoc (9-fluorenylmethoxycarbonyl) group is used as a protecting group on
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alpha amino groups in most amino acids that will be used for SPPS22. The alpha amino
group needs protecting to prevent oxidation and premature reaction of the amino acid
during storage22. While there are other protecting groups, Fmoc is popular as the primary
protecting agent because it limits contact with trifluoroacetic acid (TFA), a strong organic
acid, during the actual synthesis22. SPPS occurs in stages, starting with an insoluble resin
bead. The resin bead is an anchor for the peptide as it is built, holding on to the Cterminus. There are different types of resins for different peptide chemistries, including
Brominated Wang resin for Boc SPPS and Rink amide resin for Fmoc SPPS. After
anchoring the resin bead, the next stage is deprotection of the amino acid and removal of
Fmoc via a strong base: piperidine or piperizine22. Once deprotection has occurred,
coupling between amino acids is done using a combination of activators (Oxyma and
DIC/DCC) in a neutral environment. The process of steps is repeated until the peptide
chain is complete and the N-terminus is acetylated22. The peptide must now be cleaved
from the resin bead. To do this, a cleavage cocktail of TFA, TIS, DoDT, and MilliQ H2O
is prepared and added to the peptide to remove the peptide from the resin, as well as the
side chain protecting groups. The cleavage cocktail is important because while the TFA is
doing the main work of cleaving the peptide from the resin, the TIS and H2O are ion
scavengers, and the DoDT prevents oxidation and side reactions from the Boc/t-butyl
protected side groups that are no longer protected. After cleaving, the TFA cocktail must
be washed out of the peptide with ether and dried, and the final peptide is obtained via
dialysis and lyophilization22.
2.1.2 Hydrogel Formulation and Drug Loading
Previously published work from our group12-16, 20, 24-28 and others18, 19, 29, 30 has shown the

5

ability of an alternating (-S) serine (hydrophilic) and (-L) leucine (hydrophobic) amino
acid backbone to self-assemble into anti-parallel β-sheet nanofibers (Figure 1.1 A). We
synthesized two amphiphilic self-assembling peptides (ASPs) as shown in Table 2.1
below with SPPS. The mass spectra of the synthesized peptides are shown in Figure A.1.
We hypothesized that the charged matrices of the ASPs could modulate the prolonged
release of NLX.
Table 2.1 Sequences and Properties of ASPs
Peptide

Charge

Sequence

Form

Secondary Structure

K2

Positive

K2(SL)6K2

Hydrogel

β-sheet

E2

Negative

E2(SL)6E2

Hydrogel

β-sheet

After lyophilization, 20 mg of each ASP was dissolved in 1 ml of 298 mM
sucrose, pH adjusted to 7, to formulate 2 weight percent (2 w%) hydrogels12,

14, 15

. In

order to mix NLX into the hydrogels, NLX hydrochloride was dissolved in 298 mM
sucrose to reach 2 w% prior to combining with the hydrogels12-15,

31

. An equivalent

volume of each 2 w% NLX solution and 2 w% hydrogel were mixed to give 1 w% of
K2NLX and E2NLX. Similarly, lower concentrations of NLX hydrochloride were
prepared and mixed with hydrogels in a 1:1 ratio for release experiments described in
chapter 3.
2.2

Chemical and Ultrastructural Characterization

The secondary structure of proteins and peptides can be identified with Fourier
Transform Infrared Spectroscopy (FTIR) and Circular Dichroism (CD). FTIR uses the
unique vibration frequencies of bond types to identify them, as well as secondary

6

Figure 2.1 Fourier transform infrared (FTIR) fingerprint spectra. All (A-D) display a
characteristic β-sheet amide I peak around 1622 cm-1 and lysine side shoulders around
1673 cm-1.

7

structures such as α-helices and β-sheets. CD uses light to identify secondary protein
structures based on the polarization of light from the chiral molecules within the sample.
Surface structure and nanofiber quality is assessed by Atomic Force Microscopy (AFM),
which provides information about the height and width of the individual fibers21,

32

.

2.2.1 Fourier Transform Infrared Spectroscopy
FTIR attenuated total reflectance (FTIR-ATR) mode was used to probe the secondary
structure of the peptide hydrogels. Samples were prepared as in 2.1.2 and diluted in
MilliQ water to 0.1 mg/mL. Aqueous samples were mounted onto a cleaned potassium
bromide (KBr) plate on a Perkin-Elmer IR spectrophotometer 100 for spectral analysis
between 400-4000 cm-1, after scanning a pure MilliQ water background12-15, 17, 31. K2, E2,
K2NLX, and E2NLX were all observed (Figure 2.1) with characteristic peaks for β-sheet
specific amide I peaks at ~1620 cm-1, which confirms the amphiphilic assembly of the
(SL)6 backbone12-15,

17, 31

. There is a shoulder at ~1670 cm-1 that represents the lysine

sides, though this could also be trace remnants of trifluoroacetate from peptide synthesis.
2.2.2 Circular Dichroism
Circular

dichroism

(CD)

experiments

were

performed

on

a

Jasco

J-810

spectropolarimeter to determine the initial β-sheet secondary structure, and to ensure its
preservation after the addition of NLX. Experiments were conducted at room temperature
in a 1 m cuvette. Formulations were prepared as in 2.1.2 and diluted in MilliQ water to a
concentration of 0.1 mg/mL and scanned from 190-260 nm (Figure 2.2). Molar residual
ellipticity was then calculated and compared to references for secondary structure (αhelix and β-sheet)24. The minimum trough at ~215 nm and peak at ~195 nm for K2, E2,
K2NLX,

and

E2NLX,

indicate

8

the

presence

of

β-sheet

Figure 2.2 Circular dichroism (CD) of peptide hydrogels. All (A-D) show β-sheet
characteristic troughs around 215 nm and maxima around 195 nm, indicating that the
addition of NLX does not significantly alter the formation of the β-sheet secondary
structure.
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secondary structures within the peptide, undisturbed by the addition of NLX.
2.2.3 Atomic Force Microscopy
Atomic force microscopy (AFM) was performed to confirm peptide strand morphology
and measure nanofiber height and width. Hydrogel samples of K2, E2, K2NLX, and
E2NLX were prepared as in 2.1.2 and diluted in MilliQ water to a concentration of 0.1
mg/mL. The diluted peptide was spin-coated on a freshly cleaved mica disk. After spincoating, the sample was washed with DI water twice and dried overnight. Imaging
performed using ScanAsyst mode on a Dimension Icon instrument was used to observe
the prepared sample (Figure 2.3). The average width of K2NLX is 10.6 ± 1.6 nm, which
is consistent with the width of K2 (10.6 ± 2.7 nm). E2NLX similarly showed 8.7 ± 0.9
nm, which is consistent with the width of E2 (8.9 ± 1.2 nm)30.
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Figure 2.3 Atomic force microscopy (AFM) of diluted peptide hydrogels. All (A-D)
show individual fiber formation, showing consistent width and height (1.3-1.6 nm)
despite the addition of NLX (C, D).
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2.3

Mechanical Characterization

The peptide hydrogels that were synthesized for this work, and are generally the focus of
our group, are soft gels with relatively low tensile strength14, 20, 24. They are meant to be
injected or sprayed, similar in delivery to the current delivery mechanisms of NLX today.
In order to accurately measure the viscoelastic properties of the hydrogels, oscillatory
rheometry is performed to determine the storage and loss moduli. To be sure that the
hydrogels are injectable, we also perform strain sweep and shear recovery tests to
measure thixotropic properties.
Oscillatory rheometry was performed with a 4 mm plate geometry placed as an
upper plate and 40 μL of the prepared hydrogel loaded onto the bottom plate at a gap
length of 250 μm (n = 4). To perform the strain sweep (Figure 2.5), the loaded hydrogel
was prestrained at a constant 1% strain and a frequency of 1 Hz for 5 min and followed
by an increase in strain from 0.1 to 100% strain for 5 min. K2 and K2NLX showed
liquefaction at higher strains than E2 and E2NLX (~70% vs. ~ 30%), but all showed
inversion of G’ and G”. The addition of NLX did not affect the elastic moduli of the
hydrogels, and they exhibited similar stiffness (Figure 2.5).
For the shear recovery test (2.6) the upper plate oscillated between periods of 1%
strain for 120 s and 100% strain for 60 s, again at 1 Hz for 5 min. All four peptide
hydrogels exhibited rapid recovery of bonds in a repeatable manner when under cyclic
shear strains. The repeated shearing cycles did not cause an interruption in the storage
modulus or the rapid gelation under low-strain (>95% G’ recovery within 5 s) (Figure
2.6).
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Figure 2.4 Oscillatory shear thinning of peptide hydrogels. All (A-D) show syringe
injectability. The low strain, the elastic modulus, G’, remains higher than the viscous
modulus, G”. However, at high strain, G’ and G” show inversion and illustrate
liquefaction of the hydrogel.
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Figure 2.5 Thixotropic shear recovery of peptide hydrogels. All (A-D) exhibit
liquefaction at 100% strain, but recover rapidly into hydrogels (high G’) after removal of
strain. Minimal hysteresis noted after repeated cyclic shearing (100% strain, 60 s; 1%
strain, 120 s).
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CHAPTER 3
IN VITRO CYTOCOMPATIBILITY AND RELEASE

3.1

In Vitro Cytocompatibility

In order to assess the overall cytocompatibility of the peptides (K2, E2, K2NLX, and
E2NLX), we ran an in vitro CCK8 cytocompatibility assay with 3T3 fibroblasts. The
CCK8 assay is a sensitive colorimetric assay that uses the highly water-soluble
tetrazolium salt WST-8 to measure the dehydrogenase activity in cells. The
dehydrogenase activity generates orange formazan dye from WST-8, which is directly
proportional to the number of living cells and so can be used for measuring the
cytotoxicity of various conditions. As such, the following peptide weight percentages: 0.1
w%, 0.01w%, 0.001w% (Figure 3.1) were used in the assay. 3T3 fibroblasts were
cultured following previous protocol and seeded after the first passage from frozen. After
the first passage, fibroblasts were seeded at a cell density of 10,000 cells per well in a 96well plate (n = 5) in complete fibroblast media (90% DMEM, 10% FBS, and 1% PenStrep) for 24 h in an incubator maintained at 37 °C and 5% CO224. The fibroblast media
was aspirated, and the peptide conditions (3 w% conditions x 4 peptide types) prepared in
serum-free media were delivered to all but control (serum-free media) wells. The peptide
conditions and controls were incubated for 6 hrs. After aspirating the samples, the wells
were washed with 200 μL of PBS, and 100 μL of PBS was added to each of the wells
along with 10 μL of CCK8 stain24. After 1 h of incubation, we used a TECAN M200
Infinite plate reader to analyze the 96-well plate at an absorbance of 450 nm against a
reference wavelength of 650 nm24 as per manufacturer instructions. The results were
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analyzed with ANOVA and normalized to the media-only control (Figure 3.1).
Higher levels of cell proliferation occurred when there were higher levels of
peptide hydrogel, as the hydrogel matric mimics the ECM. Quantitatively, E2(0.1 w%) by
itself had the highest absorbance (and lowest cytotoxicity), but this is not statistically
significant compared to the media-only controls as the ANOVA values overlap.

16

Figure 3.1 Cytocompatibility assay of peptide hydrogels. No conditions exhibited
cytotoxicity relative to each other. Cell proliferation occurred at higher ECM-mimetic
hydrogel concentration levels. Analysis was performed via ANOVA, with similar Greek
letters indicating no statistically significant difference in absorption (p < 0.05).
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3.2

In Vitro Release

To measure the release of NLX from hydrogels, a colorimetric release assay was utilized.
K2 and E2 hydrogels (1 wt %) were loaded with 10 mg/mL or 1 mg/mL NLX
hydrochloride for a total of four groups. Each group was tested over two time periods.
Two hundred microliters of each NLX hydrogel was added to a microcentrifuge tube and
covered with 1 mL of 1× PBS (n = 4 per time point)26. Release experiments took place
over 30 days in an incubator maintained at 37 °C, 100% humidity, and 5% CO226. NLX
release was measured at time points: 1, 2, 4, 8, and 24 h and 2, 3, 4, 5, 6, 7, 9, 11, 13, 15,
18, 21, 24, 27, and 30 days (Figure 3.2, 3.3). At each time point, the full 1 mL of 1× PBS
was removed from the microcentrifuge tube for NLX release analysis and replaced with 1
mL of fresh 1× PBS26, 30. Release was quantified by measuring NLX absorbance at 230
nm and comparing to a NLX standard curve from 0.001 to 1.4 mg/mL using a
NanoQuant on a Tecan M200 Infinite Pro microplate reader26, 30. Reported uptake at each
time point is the average of at least two independent measurements from a total of four
independent release experiments.
NLX released from K2 and E2 hydrogels was normalized to the total NLX loaded
into the hydrogel, expressed as M/Minf26, 30. The release curves were fit against several
using SigmaPlot’s custom curve fit library, “release.jfl,” for drug release. The model with
the best fit (R2 value closest to 1) was selected to predict the release. Weibull (majority)
and Korsmeyer−Peppas (1 mg/mL E2NLX) models best predicted all data sets; for all
release curves analyzed (R2 > 0.97) (Figure 3.2, 3.3). The experimentally observed
release (points) was plotted with the release predicted by the model (solid line) and 95%
prediction bands (dashed lines).
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There was successful release of NLX from the seven day hydrogels and the thirty
day hydrogels. In the thirty day study, the 1 mg/mL gels did significantly better than the
10 mg/mL get, releasing above 80% around day 5, whereas the 10 mg/mL gels never got
reached 80%. After day 5, K2NLX(1 mg/mL) kept increasing slightly while E2NLX(1
mg/mL) was decreasing. However, both are well within the 95% prediction bands. The
seven day study again produces good release of NLX for the 1 mg/mL (above 90% by
day 4), and the 10 mg/mL group reaches the underside of 80% by the end of the study,
which is comparable to what was achieved in the thirty day study group.

19

Figure 3.2 Seven day release of NLX from peptide hydrogels. (A) K2NLX and (B)
E2NLX gels with 1 mg/mL NLX loading showed ~80% release between 4-7 days. (C)
K2NLX and (D) E2NLX gels with 10 mg/mL NLX loading showed ~80% release by 3-4
days. The release was modeled on a solid line (R2 > 0.97 for all plots) and 95% prediction
bands (dashed lines).
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Figure 3.3 Thirty day release of NLX from peptide hydrogels. (A) K2NLX and (B)
E2NLX gels with 1 mg/mL NLX loading showed ~80% release by 5 days, and continued
to release for the remainder of the study. (C) K2NLX and (D) E2NLX gels with 10
mg/mL NLX loading showed slightly less than 80% release at 5 days, and continued
releasing consistently. The release was modeled on a solid line (R2 > 0.97 for all plots)
and 95% prediction bands (dashed lines).
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CHAPTER 4
CONCLUSION AND FUTURE STEPS

4.1

Conclusion

Self assembling peptide hydrogels provide a novel scaffold for the release of small
molecule drugs. The ability to alter the mechanical properties of the gel to make it
accessible to different populations in need is especially important when considering an
application like releasing NLX, as many people might not have the training needed for
safe injections. The synthesized ASP peptide hydrogels are mechanically robust, β-sheet
forming hydrogels that can be loaded with NLX without changing the inherent properties
of the hydrogel. Our hypothesis that the hydrogel can modulate the release of NLX over
time is supported by our findings. We demonstrate that NLX can be loaded into multiple
hydrogel formulations at multiple concentrations and be released over a period of days at
high efficiency. The intact biomechanical properties of the hydrogel scaffold is important
implication in delivery of NLX, with shear stress from a needle causing liquefaction
when injected, but the bolus remaining in place for several days as the medication is
delivered.
4.2

Future Steps

The future steps for the NLX loaded hydrogels include pharmacokinetic (PK) and
pharmacodynamic (PD) testing, and in vivo models. To further understand the
mechanism of how the NLX is releasing from the hydrogel scaffold, we would run
plasma PK and PD testing. Hydrogels loaded with varying concentration of NLX, along
with pure NLX would be injected into naïve rats, and plasma would be extracted over a
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period of hours and days in order to measure the degradation rate and in vivo metabolism.
Another future step would be done in collaboration with Dr. Benedict Kolber and his
group at the University of Pittsburgh. There, opioid models of analgesia can be
performed. We would send them loaded hydrogel and naïve rats would be injected in the
back on day 0. On testing days, they would get doses of an opioid near the same spot as
the hydrogel bolus. A von Frey filament test will be performed. During the test, a small
filament is pressed to the hind paw until the animal flinches, moves away, or some other
aversive behavior is notices.
Other potential avenues of work are adding buprenorphine to the scaffold in
addition to NLX, to create a rehabilitation medication that cannot be abused. We could
also dispense opioids for pain relief after surgery instead of doctors having to prescribe
opioids with the potential for abuse, which could then lead to the need for NLX.
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APPENDIX A
MASS SPECTROSCOPY
Figure A.1 shows the mass spectroscopy of K2 and E2.

Figure A.1 Mass Spectroscopy of K2 and E2.

24

REFERENCES
1. Rzasa Lynn, R.; Galinkin, J. L., NLX dosage for opioid reversal: current evidence and
clinical implications. Ther Adv Drug Saf 2018, 9 (1), 63-88.
2. Hedegaard, H. M., Arialdi M; Warner, Margaret, Drug Overdose Deaths in the United
States, 1999-2018 Key findings Data from the National Vital Statistics System,
Mortality. Services, U. D. o. H. a. H., Ed. CDC, National Center for Health
Statistics: 2020; Vol. 356.
3. Barnett, V.; Twycross, R.; Mihalyo, M.; Wilcock, A., Opioid Antagonists. Journal of
Pain and Symptom Management 2014, 47 (2), 341-352.
4. Algera, M. H.; Kamp, J.; van der Schrier, R.; van Velzen, M.; Niesters, M.; Aarts,
L.; Dahan, A.; Olofsen, E., Opioid-induced respiratory depression in humans: a
review of pharmacokinetic-pharmacodynamic modelling of reversal. Br J Anaesth
2019, 122 (6), e168-e179.
5. Wanger, K.; Brough, L.; Macmillan, I.; Goulding, J.; MacPhail, I.; Christenson, J.
M., Intravenous vs subcutaneous NLX for out-of-hospital management of
presumed opioid overdose. Acad Emerg Med 1998, 5 (4), 293-9.
6. Kassick, A. J.; Allen, H. N.; Yerneni, S. S.; Pary, F.; Kovaliov, M.; Cheng, C.;
Pravetoni, M.; Tomycz, N. D.; Whiting, D. M.; Nelson, T. L.; Feasel, M.;
Campbell, P. G.; Kolber, B.; Averick, S., Covalent Poly(lactic acid)
Nanoparticles for the Sustained Delivery of NLX. ACS Appl Bio Mater 2019, 2
(8), 3418-3428.
7. Lewter, L. A.; Johnson, M. C.; Treat, A. C.; Kassick, A. J.; Averick, S.; Kolber, B.
J., Slow-sustained delivery of NLX reduces typical NLX-induced precipitated
opioid withdrawal effects in male morphine-dependent mice. J Neurosci Res
2020.
8. Haffajee, R. L.; Lin, L. A.; Bohnert, A. S. B.; Goldstick, J. E., Characteristics of US
Counties With High Opioid Overdose Mortality and Low Capacity to Deliver
Medications for Opioid Use Disorder. JAMA Netw Open 2019, 2 (6), e196373.
9. Kiang, M. V.; Basu, S.; Chen, J.; Alexander, M. J., Assessment of Changes in the
Geographical Distribution of Opioid-Related Mortality Across the United States
by Opioid Type, 1999-2016. JAMA Netw Open 2019, 2 (2), e190040.
10. H., H.; Bastian, B. S.; Trinidad, J. P.; Spencer, M.; Warner, M., Drugs most
frequently involved in drug overdose deaths: United States, 2011-2016. US
Department of Heath and Human Services: 2018; Vol. 67.
11. Scholl, L.; Seth, P.; Kariisa, M.; Wilson, N.; Baldwin, G., Drug and OpioidInvolved Overdose Deaths - United States, 2013-2017. MMWR Morb Mortal
Wkly Rep 2018, 67 (5152), 1419-1427.
12. Kumar, V. A.; Liu, Q.; Wickremasinghe, N. C.; Shi, S.; Cornwright, T. T.; Deng,
Y.; Azares, A.; Moore, A. N.; Acevedo-Jake, A. M.; Agudo, N. R.; Pan, S.;
Woodside, D. G.; Vanderslice, P.; Willerson, J. T.; Dixon, R. A.; Hartgerink, J.
D., Treatment of hind limb ischemia using angiogenic peptide nanofibers.
Biomaterials 2016, 98, 113-9.
13. Kumar, V. A.; Shi, S.; Wang, B. K.; Li, I. C.; Jalan, A. A.; Sarkar, B.;
Wickremasinghe, N. C.; Hartgerink, J. D., Drug-triggered and cross-linked selfassembling nanofibrous hydrogels. J Am Chem Soc 2015, 137 (14), 4823-30.

25

14. Kumar, V. A.; Taylor, N. L.; Shi, S.; Wang, B. K.; Jalan, A. A.; Kang, M. K.;
Wickremasinghe, N. C.; Hartgerink, J. D., Highly angiogenic peptide nanofibers.
ACS Nano 2015, 9 (1), 860-8.
15. Kumar, V. A.; Taylor, N. L.; Shi, S.; Wickremasinghe, N. C.; D'Souza, R. N.;
Hartgerink, J. D., Self-assembling multidomain peptides tailor biological
responses through biphasic release. Biomaterials 2015, 52, 71-8.
16. Kumar, V. A.; Wang, B. K.; Kanahara, S. M., Rational design of fiber forming
supramolecular structures. Exp Biol Med (Maywood) 2016, 241 (9), 899-908.
17. Harbour, V.; Casillas, C.; Siddiqui, Z.; Sarkar, B.; Sanyal, S.; Nguyen, P.; Kim,
K. K.; Roy, A.; Iglesias-Montoro, P.; Patel, S.; Podlaski, F.; Tolias, P.;
Windsor, W.; Kumar, V., Regulation of Lipoprotein Homeostasis by SelfAssembling Peptides. ACS Applied Bio Materials 2020, 3 (12), 8978-8988.
18. Leach, D. G.; Dharmaraj, N.; Piotrowski, S. L.; Lopez-Silva, T. L.; Lei, Y. L.;
Sikora, A. G.; Young, S.; Hartgerink, J. D., STINGel: Controlled release of a
cyclic dinucleotide for enhanced cancer immunotherapy. Biomaterials 2018, 163,
67-75.
19. Li, I. C.; Moore, A. N.; Hartgerink, J. D., “Missing Tooth” Multidomain Peptide
Nanofibers for Delivery of Small Molecule Drugs. Biomacromolecules 2016, 17
(6), 2087-2095.
20. Sarkar, B.; Nguyen, P. K.; Gao, W.; Dondapati, A.; Siddiqui, Z.; Kumar, V. A.,
Angiogenic Self-Assembling Peptide Scaffolds for Functional Tissue
Regeneration. Biomacromolecules 2018, 19 (9), 3597-3611.
21. Du, X.; Zhou, J.; Shi, J.; Xu, B., Supramolecular Hydrogelators and Hydrogels:
From Soft Matter to Molecular Biomaterials. Chem Rev 2015, 115 (24), 13165307.
22. Behrendt, R.; White, P.; Offer, J., Advances in Fmoc solid-phase peptide synthesis. J
Pept Sci 2016, 22 (1), 4-27.
23. Fields, G. B., Introduction to peptide synthesis. Curr Protoc Protein Sci 2002,
Chapter 18, Unit 18 1.
24. Nguyen, P. K.; Gao, W.; Patel, S. D.; Siddiqui, Z.; Weiner, S.; Shimizu, E.;
Sarkar, B.; Kumar, V. A., Self-Assembly of a Dentinogenic Peptide Hydrogel.
ACS Omega 2018, 3 (6), 5980-5987.
25. Nguyen, P. K.; Sarkar, B.; Siddiqui, Z.; McGowan, M.; Iglesias-Montoro, P.;
Rachapudi, S.; Kim, S.; Gao, W.; Lee, E.; Kumar, V. A., Self-Assembly of an
Anti-Angiogenic Nanofibrous Peptide Hydrogel. ACS Appl. Bio Mater. 2018, 1
(3), 865-870.
26. Nguyen, P. K.; Sarkar, B.; Siddiqui, Z.; McGowan, M.; Iglesias-Montoro, P.;
Rachapudi, S.; Kim, S.; Gao, W.; Lee, E. J.; Kumar, V. A., Self-Assembly of an
Antiangiogenic Nanofibrous Peptide Hydrogel. ACS Applied Bio Materials 2018,
1 (3), 865-870.
27. Sarkar, B.; Siddiqui, Z.; Kim, K. K.; Nguyen, P. K.; Reyes, X.; McGill, T. J.;
Kumar, V. A., Implantable anti-angiogenic scaffolds for treatment of neovascular
ocular pathologies. Drug Deliv Transl Res 2020.
28. Sarkar, B.; Siddiqui, Z.; Nguyen, P. K.; Dube, N.; Fu, W.; Park, S.; Jaisinghani,
S.; Paul, R.; Kozuch, S. D.; Deng, D.; Iglesias-Montoro, P.; Li, M.; Sabatino,
D.; Perlin, D. S.; Zhang, W.; Mondal, J.; Kumar, V. A., Membrane-Disrupting

26

Nanofibrous Peptide Hydrogels. ACS Biomaterials Science & Engineering 2019,
5 (9), 4657-4670.
29. Kim, K. K.; Siddiqui, Z.; Patel, M.; Sarkar, B.; Kumar, V. A., A self-assembled
peptide hydrogel for cytokine sequestration. J Mater Chem B 2020, 8 (5), 945950.
30. Lopez-Silva, T. L.; Leach, D. G.; Azares, A.; Li, I. C.; Woodside, D. G.;
Hartgerink, J. D., Chemical functionality of multidomain peptide hydrogels
governs early host immune response. Biomaterials 2020, 231, 119667.
31. Dong, H.; Paramonov, S. E.; Aulisa, L.; Bakota, E. L.; Hartgerink, J. D., Selfassembly of multidomain peptides: balancing molecular frustration controls
conformation and nanostructure. J Am Chem Soc 2007, 129 (41), 12468-72.
32. Webber, M. J.; Appel, E. A.; Meijer, E. W.; Langer, R., Supramolecular
biomaterials. Nat. Mater. 2016, 15 (1), 13-26.

27

